Link para a Metanálise da Cochrane Hydroxyurea (hydroxycarbamide) for sickle cell disease - Rankine-Mullings, AE - 2022 | Cochrane Library https://t.co/7CHAHMQGSS
🗓️Journée mondiale de la #drépanocytose ➡️Retour sur 4 revues @cochranecollab évaluant différents traitements dans la drépanocytose 🔸https://t.co/I2EKihjy9V 🔸https://t.co/QQAXs32Fyu 🔸https://t.co/3CLaRwEOgt 🔸https://t.co/7uOt2MWymt
RT @CochraneLibrary: #CochranePodcast - #Hydroxyurea AKA #hydroxycarbamide for people with sickle cell disease 🎧 https://t.co/Fq5iiNxIxu…
#CochranePodcast - #Hydroxyurea AKA #hydroxycarbamide for people with sickle cell disease 🎧 https://t.co/Fq5iiNxIxu ⭐️ Also on @Spotify & @ApplePodcasts 📄 Read the #CochraneReview and plain language summary: https://t.co/Axfo5idhB8 https://t.co/pu8Is
RT @cochrane_nz: Here's the latest #CochraneSystematicReview by the Cochrane Cystic Fibrosis and Genetic Disorders Group! 🧠 The systematic…
RT @cochrane_nz: Here's the latest #CochraneSystematicReview by the Cochrane Cystic Fibrosis and Genetic Disorders Group! 🧠 The systematic…
RT @cochrane_nz: Here's the latest #CochraneSystematicReview by the Cochrane Cystic Fibrosis and Genetic Disorders Group! 🧠 The systematic…
Here's the latest #CochraneSystematicReview by the Cochrane Cystic Fibrosis and Genetic Disorders Group! 🧠 The systematic review investigates hydroxyurea (or hydroxycarbamide) for people with sickle cell disease. 🌐 https://t.co/QzuVFqTcah 👥 @LBCNZ https
This librarian work won’t change what we know - evidence based - that HU is safe(long term) effective and improve survival in patients with sickle cell disease.
Hydroxyurea (hydroxycarbamide) for sickle cell disease - Rankine-Mullings, AE - 2022 | Cochrane Library https://t.co/Iql5iG5Otu